Evidence map›Paper›PMID 39442057›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026

Comparative Safety of Different Antibiotic Regimens for the Treatment of Outpatient Community-Acquired Pneumonia Among Otherwise Healthy Adults.

Anne M Butler, Katelin B Nickel, Margaret A Olsen, John M Sahrmann, Ryan Colvin, Elizabeth Neuner, Caroline A O'Neil, Victoria J Fraser, Michael J Durkin, CDC Prevention Epicenters Program

Abstract readComparative Study
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anne M ButlerDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0001-7307-6864
Katelin B NickelDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0003-4116-512X
Margaret A OlsenDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0001-7070-9320
John M SahrmannDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0001-6000-0908
Ryan ColvinDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0009-0004-3698-7457
Elizabeth NeunerDepartment of Pharmacy, Barnes-Jewish Hospital, St. Louis, Missouri, USA.
Caroline A O'NeilDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0003-2966-0750
Victoria J FraserDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0001-6251-0733
Michael J DurkinDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
CDC Prevention Epicenters Program

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Washington University Institute of Clinical and Translational Sciences (KL2) KL2TR002346 · NCATS · WASHINGTON UNIVERSITY · PI Dominic N Reeds · 2017 to 2026
$14.0M
AHRQ HHSAHRQ HHS R24 HS019455Centers for Disease Control and Prevention, Prevention Epicenters U54CK000609(NCATS) KL2TR002346NCATS NIH HHSNCATS NIH HHS KL2 TR002346NCATS NIH HHS UL1 TR002345NCEZID CDC HHS U54 CK000609NIH HHS R24 HS19455
6 · The paper itself

Abstract

backgroundEvidence is limited on the comparative safety of antibiotic regimens for treatment of community-acquired pneumonia (CAP). We compared the risk of adverse drug events (ADEs) associated with antibiotic regimens for CAP treatment among otherwise healthy, nonelderly adults.

methodsWe conducted an active-comparator new-user cohort study (2007-2019) of commercially insured adults aged 18-64 years diagnosed with outpatient CAP, evaluated via chest X-ray, and dispensed a same-day CAP-related oral antibiotic regimen. ADE follow-up duration ranged from 2 to 90 days (eg, renal failure [14 days]). We estimated risk differences [RDs] per 1000 treatment episodes and risk ratios using propensity score-weighted Kaplan-Meier functions. Ankle/knee sprain and influenza vaccination were considered as negative control outcomes.

resultsOf 145 137 otherwise healthy CAP patients without comorbidities, 52% received narrow-spectrum regimens (44% macrolide, 8% doxycycline) and 48% received broad-spectrum regimens (39% fluoroquinolone, 7% β-lactam, 3% β-lactam + macrolide). Compared with macrolide monotherapy, each broad-spectrum antibiotic regimen was associated with increased risk of several ADEs (eg, β-lactam: nausea/vomiting/abdominal pain [RD per 1000, 3.20; 95% CI, 0.99-5.73]; non-Clostridioides difficile diarrhea [RD per 1000, 4.61; 95% CI, 2.47-6.82]; vulvovaginal candidiasis/vaginitis [RD per 1000, 3.57; 95% CI, 0.87, 6.88]). Narrow-spectrum antibiotic regimens largely conferred similar risk of ADEs. We generally observed similar risks of each negative control outcome, indicating minimal confounding.

conclusionsBroad-spectrum antibiotics were associated with increased risk of ADEs among otherwise healthy adults treated for CAP in the outpatient setting. Antimicrobial stewardship is needed to promote judicious use of broad-spectrum antibiotics and ultimately decrease antibiotic-related ADEs.

Indexed as

Anti-Bacterial AgentsCommunity-Acquired InfectionsPneumoniaAdolescentAdultCohort StudiesCommunity-Acquired PneumoniaFemaleHumansMacrolidesMaleMiddle AgedOutpatientsYoung AdultAnti-Bacterial AgentsMacrolidesadministrative dataadverse drug eventsantibiotic safetyantimicrobial stewardshipcommunity-acquired pneumonia

Identifiers

PMID39442057
PMCPMC12355227

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.